Related Experiment Videos
Riluzole in Huntington's disease (HD): an open label study with one year follow up
Insights
Riluzole showed transient benefits for Huntington
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- Current treatments for HD primarily manage symptoms.
- Riluzole is an established neuroprotective agent with potential in other neurological conditions.
Purpose of the Study:
- To evaluate the safety and tolerability of riluzole in patients with Huntington's disease.
- To assess the effects of riluzole on motor, functional, cognitive, and behavioral impairments in HD.
- To explore potential symptomatic and/or neuroprotective actions of riluzole in HD.
Main Methods:
- Open-label study administering riluzole (50 mg twice daily) to nine HD patients (stages 1-3).
- Patients assessed at baseline, 3, and 12 months using the Unified Huntington's Disease Rating Scale (UHDRS).
- Safety monitoring included laboratory tests (hematology, liver enzymes) and adverse event recording.
Main Results:
- Riluzole was generally well-tolerated with no significant liver enzyme elevations.
- Transient improvements in motor function (chorea) and functional capacity observed at 3 months.
- Sustained improvements in behavioral dysfunction and psychomotor speed (Symbol Digit Modalities Test) noted at 12 months.
Conclusions:
- Riluzole demonstrates transient antichoreatic effects and sustained benefits on behavior and psychomotor speed in HD.
- The drug is safe and well-tolerated in this patient cohort.
- Further placebo-controlled trials are warranted to confirm riluzole's efficacy and mechanism in Huntington's disease.
Abstract:
In an open label study, we administered riluzole (50 mg twice a day) to nine patients with genetically confirmed Huntington's disease (HD) (clinical stages 1-3; mean age 46.4 (SD 9.3) years; mean disease duration 8 (SD 3.3) years). The study was designed to evaluate (1) safety and tolerability of riluzole and (2) effects of riluzole on motor impairment, functional disability, cognitive impairment, and behavioral abnormalities using the Unified HD Rating Scale. Patients were evaluated at baseline and after three and twelve months of riluzole therapy. Laboratory tests (hematology and liver enzymes) were repeated monthly. All adverse experiences, reported spontaneously or observed directly by the investigator, were recorded. Riluzole was well tolerated. No increase of serum liver enzymes was seen throughout the study in all but one patient showing a mild elevation. At three months, mean total motor scale (TMS), mean TMS chorea subscore, and mean total functional capacity scale were significantly improved compared with baseline. At twelve months, however, this beneficial effect on motor status and overall function was not sustained. In contrast, severity and frequency of behavioral dysfunction as well as psychomotor speed assessed by the symbol digit modalities test were improved compared with baseline. Our data suggest that there are transient antichoreatic effects and more sustained effects of riluzole on psychomotor speed and behavior in patients with HD. A double-blind, placebo-controlled trial appears highly warranted to establish definitely the symptomatic versus neuroprotective actions of riluzole in HD.